OrphoMed is a clinical-stage biotechnology company with a proprietary dimer therapeutics platform. The company is focused on developing treatments for patients with gastrointestinal disorders.
In May 2017, OrphoMed raised $39 million Series A financing. The round was led by New Enterprise Associates, and co-led by existing seed investor Takeda Ventures, Inc., with participation from other prior investors: Pappas Capital, through its newest fund, Pappas Ventures V; Relativity Healthcare Partners and the Mario Family Fund.
The capital will be used to advance the clinical development of OrphoMed's lead candidate, ORP-101, for the treatment of irritable bowel syndrome with diarrhea (IBS-D).